These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8610526)

  • 1. Main results of the first comparative clinical studies on Visipaque.
    Grynne BH; Nossen JO; Bolstad B; Borch KW
    Acta Radiol Suppl; 1995; 399():265-70. PubMed ID: 8610526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: a double-blind randomized study].
    Roriz R; de Gevigney G; Finet G; Nantois-Collet C; Borch KW; Amiel M; Beaune J
    J Radiol; 1999 Jul; 80(7):727-32. PubMed ID: 10431273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal experience with Visipaque.
    Jakobsen JA
    Eur Radiol; 1996; 6 Suppl 2():S16-9. PubMed ID: 8798051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.
    Sutton AG; Ashton VJ; Campbell PG; Price DJ; Hall JA; de Belder MA
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):346-52. PubMed ID: 12410513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate.
    Fransson SG; Stenport G; Andersson M
    Acta Radiol; 1996 Mar; 37(2):218-22. PubMed ID: 8600966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of iodixanol in healthy volunteers and patients with severe renal failure.
    Jakobsen JA
    Acta Radiol Suppl; 1995; 399():191-5. PubMed ID: 8610514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent.
    Fountaine H; Harnish P; Andrew E; Grynne B
    Acad Radiol; 1996 Sep; 3 Suppl 3():S475-84. PubMed ID: 8883524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of low and isoosmolar contrast media on renal hemodynamic in a normal and ischemic dog kidney.
    Deray G; Bagnis C; Jacquiaud C; Dubois M; Adabra Y; Jaudon C
    Invest Radiol; 1999 Jan; 34(1):1-4. PubMed ID: 9888047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodixanol in cardioangiography. A double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml.
    Tveit K; Bolz KD; Bolstad B; Haugland T; Berg KJ; Skjaerpe T; Kloster YF
    Acta Radiol; 1994 Nov; 35(6):614-8. PubMed ID: 7946687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ionic and nonionic contrast media on endothelium and on arterial thrombus formation.
    Barstad RM; Buchmann MS; Hamers MJ; Orning L; Orvim U; Stormorken H; Sakariassen KS
    Acta Radiol; 1996 Nov; 37(6):954-61. PubMed ID: 8995473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioangiography and the hemodynamic effects of iodixanol.
    Klow NE; Jacobsen EA; Refsum H
    Acta Radiol Suppl; 1995; 399():93-9. PubMed ID: 8610534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visipaque (iodixanol) and hexabrix (ioxaglate) in renal insufficiency.
    Deray G
    J Am Coll Cardiol; 2007 Apr; 49(15):1668. PubMed ID: 17433961
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME; Esplugas E; Piessens J; Rasch W
    Circulation; 2000 Jan; 101(2):131-6. PubMed ID: 10637198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in coronary angiography.
    Persson P; Liss P; Hansell P
    J Am Coll Cardiol; 2007 Apr; 49(15):1668-1669. PubMed ID: 17433962
    [No Abstract]   [Full Text] [Related]  

  • 16. Determination of glomerular filtration rate with Visipaque in patients with severely reduced renal function.
    Kjaersgaard P; Jakobsen JA; Nossen JO; Berg KJ
    Eur Radiol; 1996; 6(6):865-71. PubMed ID: 8972324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical safety assessment of contrast media: predictive value.
    Karlsson JO
    Eur Radiol; 1996; 6 Suppl 2():S3-7. PubMed ID: 8798048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial.
    Carraro M; Malalan F; Antonione R; Stacul F; Cova M; Petz S; Assante M; Grynne B; Haider T; Palma LD; Faccini L
    Eur Radiol; 1998; 8(1):144-7. PubMed ID: 9442148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac effects of iodixanol compared to those of other nonionic and ionic contrast media on the isolated rat heart.
    Dunkel JA; Bokenes J; Karlsson JO; Refsum H
    Acta Radiol Suppl; 1995; 399():142-54. PubMed ID: 8610508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.